Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of any race or ethnicity who are at least 18 years of age.~* Adult women and men with a diagnosis of fibromyalgia and stable depression (major depressive disorder, depression not otherwise specified (NOS), or dysthymia) who have been taking an antidepressant (SSRI or SNRI) primarily for their depression for at least 3 months.~Exclusion Criteria:~* Have failed pregabalin treatment due to lack of improvement of symptoms at doses of greater than or equal to 300 mg daily, cannot tolerate pregabalin or any pregabalin ingredient, or participated in a pregabalin clinical trial. If the subject has taken pregabalin and discontinued for reason other than lack of improvement or intolerance, then they will be eligible. Pregabalin use within the last 30 days (prior to V1) is not permitted.~* Patients with severe or unstable depression are not eligible.~* Patients with other types of pain or conditions that may make it difficult to evaluate fibromyalgia symptoms are not eligible~* Any subject considered at risk of suicide or self harm based on investigator judgment and/or the details of a risk assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: EXPERIMENTAL): Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
- Placebo (Type: PLACEBO_COMPARATOR): Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)

Based on this trial design, predict the completion outcome and termination type (if applicable).